Compare NX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | VALN |
|---|---|---|
| Founded | 1927 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.0M | 875.7M |
| IPO Year | 2008 | 2021 |
| Metric | NX | VALN |
|---|---|---|
| Price | $17.11 | $10.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $15.75 |
| AVG Volume (30 Days) | ★ 493.5K | 17.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,837,641,000.00 | N/A |
| Revenue This Year | $3.18 | $2.58 |
| Revenue Next Year | $2.27 | $4.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $5.43 |
| 52 Week High | $22.90 | $12.25 |
| Indicator | NX | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 27.59 | 50.40 |
| Support Level | $16.09 | $8.37 |
| Resistance Level | $19.88 | $12.22 |
| Average True Range (ATR) | 0.89 | 0.40 |
| MACD | -0.66 | -0.09 |
| Stochastic Oscillator | 7.41 | 22.94 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.